ArticleInternational journal of nanomedicine2019
Study of the interaction between self-assembling peptide and mangiferin and in vitro release of mangiferin from in situ hydrogel.
Article in International journal of nanomedicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 22 citations in OpenAlex.
- Hydrogels Activated with Plant Extracts/Bioactive Compounds for Cancer Treatment: From Design to Application.Gels (Basel, Switzerland) · 2026Review
- Sustained intravitreal delivery of carnosic acid by RADA16 peptide hydrogel protects the retina in acute ocular hypertension.Scientific reports · 2026Article
- Hydrogel-based drug delivery systems for enhanced tumor therapy.RSC advances · 2026Review
- A Baicalin Liposome-Based Temperature-Sensitive Hydrogel for Treating Ultraviolet-Induced Skin Damage.International journal of nanomedicine · 2025Article
- Synthesis of mangiferin derivatives, complexes, and carriers as potential therapeutic candidates for cancer treatment: an update.Frontiers in pharmacology · 2025Review
- Adapting to the acidic environment of the NP: RADA16-PLGA (TGF-β3) induces chondrogenic differentiation of BMSCs.Nanomedicine (London, England) · 2024Article
- Modification Strategies for Ionic Complementary Self-Assembling Peptides: Taking RADA16-I as an Example.Polymers · 2022Review
- Progress of Research in In Situ Smart Hydrogels for Local Antitumor Therapy: A Review.Pharmaceutics · 2022Review
- β-Sheet to Random Coil Transition in Self-Assembling Peptide Scaffolds Promotes Proteolytic Degradation.Biomolecules · 2022Article
- Experimental anti-tumor effect of emodin in suspension -Drug delivery · 2021Article
- Injectable antimicrobial hydrogels with antimicrobial peptide and sanguinarine controlled release ability for preventing bacterial infections.American journal of translational research · 2021Article
- High-Loading Self-Assembling Peptide Nanoparticles as a Lipid-Free Carrier for Hydrophobic General Anesthetics.International journal of nanomedicine · 2021Article
- Antitumor Effects of Self-Assembling Peptide-Emodin in situ Hydrogels in vitro and in vivo.International journal of nanomedicine · 2021Article
- Research progress in the application ofDrug delivery · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study aimed to investigate the interaction between the ion-complementary self-assembling peptide RADA16-I and the hydrophobic drug mangiferin (MA), and the potential of the self-assembling peptide to be exploited as a drug carrier of MA.
methodsThe RADA16-I-MA suspension was prepared by magnetic stirring, followed by fluorescence spectrophotometry, particle size determination, rheological properties analysis, and in vitro release assay to characterize the interaction between RADA16-I and MA. Then, the effects of in situ MA-loaded hydrogel on the proliferation of KYSE 30 and DLD-1 tumor cells and the toxic effect of the hydrogel on 293T renal epithelial cells were studied by the Cell Counting Kit 8 method.
resultsThe RADA16-I-MA suspension was formed in water under magnetic stirring; the in situ hydrogel was formed when the suspension was added to PBS. The particle size in the RADA16-I-MA suspension was around 300-600 nm with an average size of 492 nm. Within 24 h, the cumulative release of MA from the RADA16-I-MA hydrogel was about 80%. The release rate of MA from the hydrogel was dependent on the concentration of RADA16-I and the release can be fitted with a first-order kinetic equation. The results suggested that the self-assembling peptide can stabilize MA in water to form a relatively stable suspension; the results also indicated that controlled release of MA from the RADA16-I-MA in situ hydrogel formed from the RADA16-I-MA suspension can be achieved by adjusting the concentration of the peptide in suspension. The cell viability studies showed that the RADA16-I-MA in situ hydrogel not only can maintain or enhance the intrinsic proliferation inhibition effects of MA on tumor cells, but also can reduce the toxicity of MA to normal cells.
conclusionThe self-assembling peptide RADA16-I can be a potential candidate for constructing a delivery system of the hydrophobic drug MA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.